Gastro I. s.r.o. — Clinical Trial Site

30 Registered trials

7 Currently recruiting

Organisation

Gastro I. s.r.o.

Location

Presov, Slovakia

Identifier

ORG-100045610

Address

Puskinova 18, 080 01, Slovakia

Departments

Additional site address: Puskinova 18, 080 01 Presov
Gastoenterologicka ambulancia
Gastroenterológia
Gastroenterologicka ambulancia
gastroenterology
Gastroenterology Clinic
Gastrological clinic
N/A
NA
Outpatient care for Gastroenterology
SK10001, Gastroenterologicka ambulacia
SK10002: Gastroenterologicka ambulacia
SK10003: Gastroenterologicka ambulancia
SK10004: Gastroenterologicka ambulacia

Clinical trials at this site (30)

Search interface

A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Pending

2025-521038-27-00 Immune system diseases 5
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting

2023-508158-24-00 Moderately to Severely Active Crohn’s Disease 4 2024-06-25
A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended

2023-510487-12-00 Crohn's Disease 4 2024-11-29
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended

2022-500953-17-00 Moderately to severely active ulcerative colitis 4 2023-03-23
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended

2023-504737-41-00 Moderately to Severely Active Crohn's Disease 5 2022-06-10
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Moderate to Severe Ulcerative Colitis 4 2021-12-01
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended

2022-501645-70-00 Crohns Disease 5 2020-11-25
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Ulcerative Colitis 5 2017-01-02
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03